Life Sciences Report

The Life Sciences Report, by Streetwise Reports, is the leading source of investment coverage of Biotech, Pharmaceuticals, Medical Devices, Tools & Diagnostics.

[Life Sciences Report @SWLifeSciences]

US Biotech Co. Targets Muscular Dystrophy with First-In-Class Drug
https://t.co/aaSi4WLs9X

Capricor Therapeutics Inc.'s ( $CAPR ) Deramiocel targets FDA approval by August 2026, with analysts issuing Buy ratings and price targets as high as US$60.

[Life Sciences Report @SWLifeSciences]

New Alzheimer's Imaging Push Expands as Financing Terms Get Investor-Friendly
https://t.co/qXYo77vQOp

Grey Matters Health Inc. ( $GREY.CN $AGNPF ) amended warrant terms tied to its CA$1 million private placement as it advances plans for a U.S. brain-specific neuroimaging clinic focused on Alzheimer's diagnostics.

[Life Sciences Report @SWLifeSciences]

Biopharma Company Reveals High-Impact SCI Recovery Gains
https://t.co/xPalG7B08e

NervGen Pharma Corp. ( $NGEN.V $NGENF ) reports 100% responder rates for NVG-291 in spinal cord injury trials, strengthening hopes for major recovery breakthroughs.

[Life Sciences Report @SWLifeSciences]

200 Brain PET Scans, 162 Alzheimer's Drugs: A Diagnostic Push Takes Shape
https://t.co/LBMzhvjwcO

Grey Matters Health Inc. ( $GREY.CN $AGNPF ) signed an LOI tied to a minimum of 200 brain PET scans for an Alzheimer's clinical trial while expanding its NovaScan neuroimaging strategy.

[Life Sciences Report @SWLifeSciences]

Cleantech Co. Wins PFAS Deal, Engineering Pact, Ships Clyra
https://t.co/qXSxS31MIy

BioLargo ( $BLGO ) shipped Clyra's first stocking order, signed Aquatech PFAS MOU, and won a US$1.2M engineering contract for a minerals processing facility, according to an Oak Ridge Financial research note.

@BioLargo

[Life Sciences Report @SWLifeSciences]

Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans
https://t.co/8nuVxeoOHX

Keros Therapeutics Inc. ( $KROS ) lowered research spending & reported funding through 2028 as analysts monitor upcoming trial catalysts for ALS & Muscular Dystrophy drugs.

[Life Sciences Report @SWLifeSciences]

Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles
https://t.co/DMyjXiYxEf

Keros Therapeutics ( $KROS ) disclosed that initiation of its Phase 2 rinvatercept study in Duchenne muscular dystrophy will slip from 2Q26 to 3Q26 due to procedural regulatory delays, according to a Wedbush research note.

[Life Sciences Report @SWLifeSciences]

New York Digital Health Firm Expands Reach to 116 Million Covered Lives
https://t.co/t9ncez9Xr8

DarioHealth Corp. ( $DRIO ) reported first quarter 2026 results showing sequential revenue growth, lower operating expenses, expanded channel partnerships and a US$127 million commercial pipeline.

[Life Sciences Report @SWLifeSciences]

Biotech Co. Unveils Scalable AI Voice Biomarker Platform
https://t.co/C4d21MphmP

MindBio Therapeutics Corp.'s ( $MBIO.CN $MBQIF ) CEO says proprietary AI voice analytics could transform impairment screening across zero-tolerance industries.

@MindBioTherap

[Life Sciences Report @SWLifeSciences]

FDA Fast Track Designation Boosts ALS Treatment Outlook; Analyst Sees More Than 250% Upside Potential
https://t.co/p7HXSn6PQk

D. Boral Capital analyst Jason Kolbert reiterated his rating and price target on Coya Therapeutics Inc. ( $COYA ) following the company's receipt of FDA Fast Track Designation for COYA 302 in ALS.

[Life Sciences Report @SWLifeSciences]

Biotech Co. Advances AI Detection Breakthrough for Intoxication Safety
https://t.co/19Cz41h8mR

MindBio Therapeutics Corp. ( $MBIO.CN $MBQIF ) enhances AI speech analysis tech with cross-language capability, paving the way for major accident-prevention potential.

@MindBioTherap

[Life Sciences Report @SWLifeSciences]

California Biotech Co. Discovers VOXZOGO Breakthrough, Reports Strong Q1
https://t.co/ApYt8jBuM5

BioMarin Pharmaceuticals Inc. ( $BMRN ) delivered positive long-term achondroplasia data alongside rising revenues, accelerating rare disease portfolio growth.

[Life Sciences Report @SWLifeSciences]

Sublingual Drug Reformulator Expands into Caffeine Market and Gets Capital Injection
https://t.co/aIrbx2ow89

Technical Analyst Stewart Thomson reviews Aspire Biopharma Holdings, Inc. ( $ASBP ) in light of its recent news.

[Life Sciences Report @SWLifeSciences]

CleanTech Company Advances Global PFAS Water Treatment Partnership with Aquatech
https://t.co/WgMeh0MTVQ

Cleantech and life sciences innovator BioLargo Inc. ( $BLGO ) notches multiple wins this week for the distribution of its products worldwide.

@BioLargo

[Life Sciences Report @SWLifeSciences]

Biotech Innovator Niagen Uncovers Breakthrough NAD+ Booster, Reports Strong Q1 Results
https://t.co/xVuXL5OCaY

Niagen Bioscience Inc. ( $NAGE ) reports a 3% increase in total net sales to US$31.5 million for the first quarter. Read why analysts recommend this stock in a rapidly expanding market.

[Life Sciences Report @SWLifeSciences]

FDA Rejects Melanoma Drug Again as Analysts Slash Targets and Approval Path Comes Under Fire
https://t.co/tYtNFehxLq

Replimune Group Inc. ( $REPL ) received a second FDA rejection for RP1 in advanced melanoma, prompting analyst downgrades, price target cuts, and renewed debate over approval standards for cancer therapies.

[Life Sciences Report @SWLifeSciences]

Three AI-Driven Cancer Programs Advance Toward Key 2026 Milestones
https://t.co/CU3SubwKUO

Rakovina Therapeutics Inc. ( $RKV.V ) reported 2025 financial results and outlined progress across its kt-5000, kt-3283, and kt-2000 programs, alongside financing, leadership updates, and ongoing AI partnerships.

[Life Sciences Report @SWLifeSciences]

Oncology Company Given Neutral Rating as Q1/26 Beat Sets Up Catalyst
https://t.co/rYyf9gkMpN

Wedbush Securities reiterated a Neutral rating on Novocure Ltd. ( $NVCR ) after the company posted a Q1/26 revenue beat of US$174.1 million, raised FY26 guidance to US$690710 million, and reported encouraging early Optune Pax launch metrics.

[Life Sciences Report @SWLifeSciences]

Oncology Co. Tests Advanced Cancer Treatments, Reports Q1 2026 Financial Results
https://t.co/3XtCyAsUNX

Novocure Ltd. ( $NVCR ) posted 12% revenue growth, strong international patient gains, FDA momentum, and promising pancreatic cancer trial results in 2026.

[Life Sciences Report @SWLifeSciences]

MA Biotech Downgraded to Neutral After Second FDA CRL for RP1 Melanoma BLA
https://t.co/TRl6GZM8N1

Wedbush Securities downgraded Replimune Group Inc. ( $REPL ) to NEUTRAL after the FDA issued a second complete response letter for RP1 in PD-1 refractory melanoma.